<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578213</url>
  </required_header>
  <id_info>
    <org_study_id>ISAV</org_study_id>
    <secondary_id>2011-002749-37</secondary_id>
    <nct_id>NCT01578213</nct_id>
  </id_info>
  <brief_title>Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients</brief_title>
  <acronym>ISAV</acronym>
  <official_title>Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the capability of the dPCR technique to predict the
      absence of disease relapses after imatinib discontinuation in CML patients with negative
      Q-RT-PCR results for longer than 18 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit approximately 100 CML patients under imatinib therapy in complete
      molecular remission with a history of at least 18 months of consecutive negative standard
      Q-RT-PCR as performed in their own centers. After signing the informed consent form (ICF),
      the patients will be tested for dPCR and will discontinue imatinib therapy. Then they will be
      monitored by standard Q-RT-PCR to assess the maintenance of the molecular remission;
      collection of data will be prospective as each center will collect the data for 36 months. At
      the end of this period, a peripheral blood sample for dPCR analysis will be obtained from
      those patients who will still have undetectable BCR-ABL transcripts by Q-RT-PCR to verify CML
      eradication. The maintenance of molecular remission by Q-RT-PCR and the survival will be
      monitored every six months during an additional follow-up of 24 months. Patients found to be
      positive to BCR-ABL transcripts by standard Q-RTPCR will repeat the test every 2 to 4 weeks
      until the loss of molecular remission, defined as two consecutive BCR-ABL positive tests with
      at least one with BCR-ABL/BCR value above 0.1%, or until the end of the study, whichever come
      first.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Negative Predicted Value Ratio (rNPV) of dPCR over Q-RT-PCR</measure>
    <time_frame>At 36 months.</time_frame>
    <description>The capability of the dPCR method to predict relapse-free patients relative to the standard method. NPV of each method will be computed as the number of patients who are negative according to either method at the time of imatinib discontinuation and remain relapse-free 36 months later over the total of negative patients according to either method, respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular and cytogenetic relapse</measure>
    <time_frame>At 36 months</time_frame>
    <description>Rate of molecular and cytogenetic relapse after discontinuation of imatinib treatment out of total number of patients enrolled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of dPCR positive patients</measure>
    <time_frame>At 36 months</time_frame>
    <description>Rate of patients who are dPCR positive before discontinuation of imatinib and who do not relapse within the following 36 months (false positive) out of the total number of relapse-free patients at month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of dPCR negative patients</measure>
    <time_frame>At 36 months</time_frame>
    <description>Rate of patients who are dPCR negative before discontinuation of imatinib and who relapse (false negative) out of the total number of patients relapsing within the following 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who are maintaining dPCR negativity for 36 months</measure>
    <time_frame>At 36 months</time_frame>
    <description>Rate of patients who are maintaining dPCR negativity for 36 months over the patients who are Q-RT-PCR negative at the end of the interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to molecular relapse</measure>
    <time_frame>At 36 months</time_frame>
    <description>Time to molecular relapse, both from the first PCR-negative and from the discontinuation of imatinib to the time of loss of molecular response, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At the end of the study</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At 36 months</time_frame>
    <description>Quality of Life, as measured by the Global Health Status\QOL and other subscales scores of EORTC-QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients progressing or developing resistance</measure>
    <time_frame>At 36 months</time_frame>
    <description>Rate of patients progressing or developing resistance after imatinib resumption out of total number of patients enrolled</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
    <description>Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg
Total dosage per day: 800 mg
Oral use</description>
    <arm_group_label>Imatinib</arm_group_label>
    <other_name>Glivec, Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated IRB/IEC-approved Informed Consent

          2. Age&gt;=18 years

          3. Male or female patients with CML diagnosed in chronic or accelerated phase and who
             have been treated for more than 2 consecutive years with imatinib therapy

          4. Sustained Complete Molecular Response (as defined by the treating center) for at least
             18 months with imatinib treatment

          5. A minimum of 3 CMR determined by Q-RT-PCR analysis to support disease status, with the
             list one performed within 3 calendar months prior to enrollment date

          6. Willingness and ability to comply with scheduled visits laboratory tests and other
             study procedures

        Exclusion Criteria:

          1. Allogenic hematopoietic stem cell transplantation

          2. Known active infections including human immunodeficiency virus (HIV) positivity

          3. Current enrollment another clinical trial

          4. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration or may interfere with the interpretation of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Gambacorti-Passerini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Ospedaliera San Gerardo di Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eros Di Bona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S. Bortolo (USSL 6)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Di Raimondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria &quot;Policlinico - Vittorio Emanuele&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabetta Abruzzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università di Tor Vergata Ospedale di S. Eugenio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca Arcaini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Matteo Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valeria Santini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università di Firenze Azienda Ospedaliera-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Martino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Bianchi-Melacrino-Morelli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandra Iurlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ester Pungolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Niguarda Ca' Granda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp le Coutre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University of Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarit Assouline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University - Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Onno Leeskma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouwe Gasthuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcio Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Micaela Bergamaschi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS A.O.U. San Martino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University - Jewish General Hospital Division of Hematology and Department of Oncology</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University of Berlin - Clinic of Medicine - Hematology and Oncology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center - Division of Hematology, BMT and CBB</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Policlinico-Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <state>Italy/Catania</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Firenze Azienda Ospedaliera - Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Italy/Firenze</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Italy/MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC di Ematologia</name>
      <address>
        <city>Milano</city>
        <state>Italy/Milano</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo Pavia - Istituto di Ematologia</name>
      <address>
        <city>Pavia</city>
        <state>Italy/Pavia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi-Melacrino-Morelli U.O. Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <state>Italy/Reggio Calabria</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Tor Vergata Ospedale S. Eugenio</name>
      <address>
        <city>Rome</city>
        <state>Italy/Rome</state>
        <zip>00142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo (USSL 6)</name>
      <address>
        <city>Vicenza</city>
        <state>Italy/Vicenza</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca' Granda - U.O. Ematologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet - Hematologia</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

